Lactate decreases TG-VLDL synthesis by the liver by decreased production. Since patients with FCH have a higher production, we hypothesize that they will have a significant decrease in their production.
ID
Bron
Verkorte titel
Aandoening
familial combined hyperlipidemia
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
TG-VLDL synthesis by the liver measured by stable glycerol isotopes every hour. With the rate of disappearance curve synthesis will be calculated.
Achtergrond van het onderzoek
TG-VLDL synthesis by the liver will be studied during lactate vs saline infusion and in some patients MRS will be applied.
Doel van het onderzoek
Lactate decreases TG-VLDL synthesis by the liver by decreased production. Since patients with FCH have a higher production, we hypothesize that they will have a significant decrease in their production.
Onderzoeksopzet
8 hours per intervention. There are two visits with one intervention with two weeks between them.
Onderzoeksproduct en/of interventie
1. One day of venous lactate infusion and one day of saline infusion as a control, in healthy subjects and FCH patients;
2. MRS scan of the brain will be done before the start of the infusion and at the end of the infusion.
Publiek
Academic Medical Center Amsterdam
Amsterdam
The Netherlands
+31 (0)205669111
b.m.sondermeijer@amc.uva.nl
Wetenschappelijk
Academic Medical Center Amsterdam
Amsterdam
The Netherlands
+31 (0)205669111
b.m.sondermeijer@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Healthy participants inclusion:
1. Male;
2. BMI < 26 kg/m2;
3. Age 18-65 yrs;
4. Normal HbA1c level;
5. Normal renal and liver function (creatinine < 150 umol/L, normal liver enzymes);
6. Not on any medication affecting glucose or lipid metabolism or affecting brain regulation (anti-depressants/anti-convulsants);
7. Alcohol intake less than 2 units per day;
8. No claustrophobia in the view of the MRS;
9. No foreign metal devices in the view of the MRS;
10. No panic disorder.
Inclusion criteria for people with FCH:
1. FCH patients meet the criteria of the nomogram of Veerkamp(37);
2. Inclusion criteria 3-9 are identical to healthy participants;
3. Males, matched with healthy participants for age;
4. BMI<27 kg/m2;
5. Triglyceride levels >2.5 mmol/l;
6. No relevant active disease;
7. No known cardiovascular disease;
8. No statins intake for at least 6 weeks.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Medication influencing the brain.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL2414 |
NTR-old | NTR2522 |
Ander register | METC : 09/010 |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |